The White House and the Department of Health and Human Services will convene experts to discuss the benchmarking and ...
A study of Lilly's retatrutide weight loss drug in people with heart disease did not answer a crucial question — whether it ...
Timothy Westlake, an emergency doctor nominated to head SAMHSA, has been active in addiction policy in Wisconsin.
Has a wanted fugitive been posing as a biotech executive? And what does it take to develop a therapy for an ultra-rare ...
Mirroring the bipartisan bill introduced in the House, the measure would require a study from the GAO on the state of men’s ...
New data supports the idea that Merck’s Ebola vaccine Ervebo, licensed to target the Zaire species of ebolaviruses, could ...
Pharmaceutical leaders are trying to convince policymakers to back off pushes for aggressive restrictions on investments in ...
The panel recommended allowing compounding pharmacies to produce popular but unproven BPC-157 and KPV peptides.
On analyses that looked at major cardiovascular events, those taking retatrutide did not have a significant lower risk of death, heart attack, or stroke.
Veterans who want to rejoin the military are often bogged down in bureaucratic red tape.
FDA advisers are set to consider whether allowing compounding pharmacies to offer largely unproven peptides is a safer bet than the gray-market versions now in use.
New maternal billing codes should create a transparent system where both patients and clinicians can thrive, ACOG writes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results